Sevoflurane (SevoFlo)

Sevoflurane is a fluorinated methyl isopropyl ether inhalant anesthetic agent that has gained significant popularity in small mammal veterinary medicine due to its rapid induction and recovery characteristics. This volatile liquid anesthetic produces general anesthesia through depression of central nervous system activity, similar to other halogenated agents, but its unique physical properties result in faster transitions between anesthetic planes. The medication is administered through a precision vaporizer specifically calibrated for sevoflurane, delivering the agent as a measured concentration in oxygen carrier gas through face masks, induction chambers, or endotracheal tubes depending on patient size and procedure requirements.

Developed in the 1970s and introduced for clinical use in the 1990s, sevoflurane represented an advancement over existing inhalant anesthetics due to its low blood-gas partition coefficient, which translates to more rapid equilibration between inspired concentration and brain concentration. This pharmacokinetic property means that small mammal patients lose consciousness more quickly during induction and regain consciousness more quickly during recovery compared to isoflurane. The pleasant, non-pungent odor of sevoflurane reduces breath-holding and struggling during mask induction, which is particularly advantageous when anesthetizing fractious or easily stressed small mammals.

Sevoflurane is available exclusively as a volatile liquid in specialized bottles designed for use with sevoflurane-specific vaporizers. The clear to light yellow liquid has a mild, slightly sweet odor that patients generally tolerate better than the pungent smell of isoflurane. No oral, injectable, or compounded formulations exist, and the medication can only be administered through vaporization in properly calibrated equipment. Veterinary facilities require sevoflurane-specific vaporizers, as the physical properties differ from isoflurane and cross-contamination between different inhalant agents creates dangerous situations with unpredictable delivered concentrations.

The effectiveness and safety profile of sevoflurane in small mammals is well-established through extensive clinical use across numerous species in both veterinary and research settings. The agent provides reliable, controllable anesthesia with the significant advantage of rapid transitions that reduce time in vulnerable intermediate planes during induction and recovery. Sevoflurane undergoes slightly more hepatic metabolism than isoflurane but still has an excellent safety profile regarding organ toxicity. The faster kinetics are particularly valuable in small mammals whose high metabolic rates and limited reserves make prolonged recovery periods risky. However, sevoflurane is typically more expensive than isoflurane, which influences its adoption in cost-sensitive practice settings despite its clinical advantages.

The primary use of sevoflurane in small mammal medicine is the induction and maintenance of general anesthesia for procedures requiring complete unconsciousness and immobility, with particular value in situations where rapid induction, smooth transitions, and fast recovery are desirable. Surgical procedures benefiting from sevoflurane include spaying and neutering, mass removal, dental extractions, orthopedic repairs, and abdominal exploratory surgery. The controllable anesthetic depth allows veterinarians to titrate precisely to procedure requirements while sevoflurane's rapid kinetics enable quick adjustments when surgical stimulation changes or when complications require immediate lightening of anesthesia.

Species-specific applications of sevoflurane span the full range of small mammals encountered in exotic practice, with the agent's smooth induction characteristics particularly valued in easily stressed species. Ferrets commonly receive sevoflurane for adrenal surgery, insulinoma treatment, and foreign body removal, benefiting from rapid recovery that minimizes hypoglycemia risk in insulinoma patients. Guinea pigs with their sensitivity to stress appreciate sevoflurane's non-irritating nature during mask induction for dental procedures. Chinchillas undergoing necessary procedures benefit from fast recovery that reduces time spent at dangerous body temperatures. Hamsters, gerbils, and other small rodents experience less struggling during induction due to the pleasant odor.

Diagnostic procedures constitute an important indication for sevoflurane anesthesia in small mammals, particularly when rapid recovery enables same-day discharge. Radiographic imaging requiring brief immobility can be accomplished with mask sevoflurane induction, brief maintenance while images are obtained, and recovery within minutes of discontinuation. Advanced imaging including computed tomography and magnetic resonance imaging requires longer anesthetic periods but still benefits from smooth induction characteristics. Ultrasound examinations produce better diagnostic results with optimal patient positioning under anesthesia. Sample collection procedures including blood draws, bone marrow aspirates, and cerebrospinal fluid taps can be performed humanely with sevoflurane anesthesia and rapid recovery.

Off-label applications of sevoflurane include its use for chemical restraint during procedures that fall short of requiring full surgical anesthesia but benefit from patient immobility and reduced stress. Wound management, bandage changes, and therapeutic procedures can be accomplished more thoroughly with light sevoflurane sedation. Some practitioners utilize brief sevoflurane exposure to facilitate handling of aggressive patients for examination or sample collection. Emergency situations requiring immediate anesthesia for stabilization procedures benefit from sevoflurane's rapid onset. High-risk patients who might not tolerate prolonged induction or recovery periods associated with slower agents may be candidates for sevoflurane.

Sevoflurane is often selected over isoflurane when its specific advantages outweigh its higher cost. Patients presenting with extreme stress, aggression, or respiratory compromise benefit from the faster, smoother induction that minimizes struggle and breath-holding. Procedures requiring very brief anesthesia benefit from sevoflurane's rapid recovery that reduces total anesthetic time. Patients at risk from prolonged recovery, such as those with hypoglycemia risk or compromised thermoregulation, benefit from faster return to consciousness. Training situations where demonstration of rapid anesthetic transitions is valuable may utilize sevoflurane. Some practitioners prefer sevoflurane for all small mammal cases based on their assessment that the clinical advantages justify the increased cost.

General dosing principles for sevoflurane in small mammals require individualization based on species, patient health status, concurrent medications, and procedure requirements, with all anesthetic protocols designed and supervised by veterinarians experienced in exotic animal anesthesia. Unlike injectable medications with specific milligram dosing, sevoflurane is administered as a percentage concentration in inspired gas, with the veterinarian continuously adjusting vaporizer settings based on monitoring parameters and clinical assessment of anesthetic depth. The generally higher vaporizer settings required for sevoflurane compared to isoflurane reflect its different physical properties rather than greater potency. Specific numeric concentrations are not provided here as they vary substantially between species and circumstances and must be determined by the attending exotic veterinarian.

Route of administration for sevoflurane requires specialized equipment including a sevoflurane-specific precision vaporizer, oxygen source with appropriate flowmeters, breathing circuit, and waste gas scavenging system. Small mammals may be induced in a clear anesthesia chamber where the sevoflurane concentration can be observed, after which they are transferred to face mask for maintenance. The non-pungent odor of sevoflurane makes mask induction more feasible than with isoflurane, as patients are less likely to breath-hold or struggle. Endotracheal intubation provides superior airway control in appropriately sized patients like ferrets and larger rabbits. The choice between chamber induction, mask induction, and maintenance methods depends on patient factors and available equipment.

Frequency and duration of sevoflurane anesthesia should be minimized to clinical necessity, though the rapid recovery characteristics may allow slightly longer safe anesthetic periods compared to slower agents in some circumstances. Short procedures may require only minutes of anesthesia with recovery occurring within minutes of discontinuation. Complex procedures necessitate longer maintenance but benefit from sevoflurane's rapid depth adjustment capability. Repeated anesthetic episodes should be spaced appropriately to allow full recovery between events. Pre-anesthetic fasting recommendations vary by species, with ferrets typically fasted briefly while most rodents and rabbits should not be fasted due to their gastrointestinal physiology and hypoglycemia risk.

Species-specific considerations significantly influence sevoflurane protocols in small mammals. Ferrets tolerate sevoflurane well with predictable responses and feasible intubation. Guinea pigs and chinchillas have challenging airway anatomy favoring mask maintenance, but sevoflurane's smooth induction is particularly valuable for these stress-sensitive species. Very small rodents including hamsters, gerbils, and mice benefit from sevoflurane's rapid kinetics that allow quick rescue if problems develop. Hedgehogs' defensive curling behavior may be overcome more quickly with sevoflurane's faster induction characteristics. Rabbits, while sensitive to respiratory depression regardless of agent, may benefit from sevoflurane's rapid recovery capabilities.

No compounding of sevoflurane is possible or necessary, as the medication is used in its manufactured liquid form within calibrated vaporizers. Critical equipment requirements for small mammal sevoflurane anesthesia include appropriately sized breathing circuits with minimal dead space, non-rebreathing circuit configurations for very small patients, properly fitting face masks, and pediatric monitoring equipment. The sevoflurane vaporizer must be calibrated specifically for this agent and not contaminated with other anesthetics. Temperature-compensated vaporizers maintain consistent output across varying operating room temperatures. Small animal and exotic-specific anesthesia setups are available from various manufacturers.

Owner involvement in sevoflurane administration is minimal, as the medication requires professional veterinary administration with specialized equipment in a controlled clinical environment. Owners should understand that their pet will be unconscious during the procedure and monitored continuously by trained staff. Recovery from sevoflurane is typically quite rapid, with many patients becoming alert within minutes of anesthetic discontinuation. Post-anesthetic care instructions should include monitoring for normal behavior, appetite return, and elimination appropriate to the species. Some residual effects may persist for several hours despite rapid initial awakening, and the animal should be kept safe and warm until fully coordinated.

Common side effects of sevoflurane anesthesia in small mammals are similar to those seen with other inhalant anesthetics and relate to the expected pharmacologic effects of general anesthesia. Dose-dependent respiratory depression occurs in all patients, manifesting as decreased respiratory rate, reduced tidal volume, and potential need for ventilatory support during deeper anesthetic planes. Cardiovascular depression including reduced heart rate and blood pressure represents another expected effect that is generally well-tolerated in healthy patients but may compromise animals with underlying cardiovascular disease. Hypothermia develops rapidly in anesthetized small mammals due to their high surface area to volume ratio and impaired thermoregulation, necessitating active warming throughout the procedure and into recovery.

Gastrointestinal effects following sevoflurane anesthesia are typically minimal and transient, which is particularly important for small mammals susceptible to gastrointestinal stasis. Some reduction in appetite may occur in the immediate post-anesthetic period but generally resolves quickly, especially with sevoflurane's rapid recovery characteristics that allow patients to return to eating sooner than with slower agents. Guinea pigs, chinchillas, and rabbits should be monitored for resumption of normal eating and fecal production, as any prolonged anorexia can trigger serious gastrointestinal complications. Offering favored foods soon after recovery encourages normal gastrointestinal function restoration. Sevoflurane does not typically cause prolonged ileus or significant gastrointestinal disruption.

Species-specific adverse reactions to sevoflurane are relatively uncommon but individual variation exists across the small mammal species. Ferrets generally handle sevoflurane excellently with predictable, smooth responses during induction and recovery. Guinea pigs may experience respiratory depression requiring supplemental oxygen support during and after anesthesia. Chinchillas are sensitive to hyperthermia during any anesthetic event and require careful temperature management. Rabbits remain sensitive to respiratory depression regardless of inhalant agent choice and benefit from careful monitoring. Small rodents have extremely rapid metabolic rates that can make adverse events develop and progress quickly, though sevoflurane's fast kinetics also allow rapid intervention.

Serious and rare side effects of sevoflurane include the theoretical concern of compound A formation when sevoflurane reacts with carbon dioxide absorbents in circle breathing systems, though this is primarily a concern with low fresh gas flows in human anesthesia and is minimized in small mammal practice where non-rebreathing circuits are typically used. Malignant hyperthermia remains a rare possibility with any volatile anesthetic. Severe hypotension can occur with deep anesthesia or underlying cardiovascular compromise. Cardiac arrhythmias are possible, though sevoflurane may have fewer arrhythmogenic properties than some alternatives. Respiratory arrest can occur with overdose, and prolonged recovery may indicate underlying pathology or complications.

Owners should contact their veterinarian immediately if their small mammal displays concerning signs following sevoflurane anesthesia despite the expected rapid recovery. Warning signs requiring immediate attention include failure to become alert within the expected rapid timeframe, respiratory difficulty including open-mouth breathing or labored respirations, extreme lethargy persisting beyond several hours post-procedure, failure to eat or drink within the expected recovery period for the species, signs of pain such as teeth grinding or hunched posture, and any neurologic abnormalities. While sevoflurane's rapid recovery is an advantage, owners should still monitor their pet carefully and report any concerns to the veterinary team.

True species-specific contraindications to sevoflurane are minimal, as the agent can be used across virtually all small mammal species when administered by experienced practitioners with appropriate equipment and monitoring capabilities. The generally excellent tolerance of sevoflurane across species makes absolute contraindications rare. However, certain patient factors affect risk assessment and require careful consideration rather than creating absolute prohibitions on use. Extremely debilitated animals of any species may not tolerate the cardiovascular and respiratory depression inherent to any general anesthetic. Patients in respiratory distress require careful evaluation, as the induction period, even with sevoflurane's rapid characteristics, may be dangerous before airway support can be established.

Medical condition contraindications to sevoflurane include significant cardiovascular disease, severe respiratory compromise, and shock or severe dehydration. Patients with pre-existing cardiac arrhythmias require careful evaluation, though sevoflurane may be less arrhythmogenic than some alternatives. Severe respiratory pathology including pneumonia, pleural effusion, or obstructive airway disease increases anesthetic risk substantially. While sevoflurane undergoes slightly more hepatic metabolism than isoflurane, severe hepatic disease still warrants caution with any anesthetic protocol. Hypovolemic patients benefit from stabilization with fluid therapy before anesthesia when the clinical situation allows. Patients with suspected or confirmed renal disease require consideration of the compound A issue, though this is primarily relevant in closed-circuit systems rarely used in small mammals.

Age and reproductive status considerations apply to sevoflurane use in small mammals similarly to other anesthetic agents. Very young animals may have immature organ function affecting their overall anesthetic risk, though sevoflurane's minimal metabolism makes it relatively safe compared to injectable alternatives heavily dependent on hepatic biotransformation. Geriatric animals often have subclinical dysfunction in multiple organ systems that increases anesthetic risk and warrants thorough pre-anesthetic evaluation. Pregnancy is not an absolute contraindication when maternal health requires intervention, but sevoflurane crosses the placenta and affects fetal physiology. Nursing mothers can be anesthetized for necessary procedures with attention to full recovery before reunion with dependent offspring.

Circumstances where sevoflurane should not be used include lack of appropriate sevoflurane-specific vaporizer equipment, inadequate monitoring capabilities, or absence of personnel trained in managing anesthetic complications in small mammals. Using isoflurane vaporizers with sevoflurane or vice versa creates dangerous unpredictability in delivered concentrations. Procedures accomplishable with local anesthesia or brief manual restraint may not warrant general anesthesia risks. Elective procedures should be postponed in patients with concerning pre-anesthetic findings until underlying issues are addressed. The higher cost of sevoflurane compared to isoflurane may influence agent selection when both would be clinically appropriate. Facilities without emergency resuscitation capabilities should refer anesthetic cases appropriately.

Medications requiring careful consideration when combined with sevoflurane include other central nervous system depressants that produce additive or synergistic respiratory and cardiovascular depression. Opioid analgesics commonly used in balanced anesthesia protocols potentiate respiratory depression while reducing sevoflurane concentration requirements, requiring adjusted monitoring and potential ventilatory support. Benzodiazepines used for premedication enhance central nervous system depression and typically reduce the sevoflurane requirement for induction and maintenance. Alpha-2 adrenergic agonists like dexmedetomidine produce profound synergistic effects with inhalant anesthetics, dramatically reducing required concentrations while significantly affecting cardiovascular function. These intentional drug combinations form the basis of modern balanced anesthesia but require experienced management.

Drug interactions affecting sevoflurane efficacy or producing safety concerns include neuromuscular blocking agents whose effects may be prolonged under inhalant anesthesia. Aminoglycoside antibiotics can potentiate neuromuscular blockade when used concurrently. Catecholamines and sympathomimetic drugs theoretically could interact with sevoflurane, though sevoflurane has less cardiac sensitizing effect than older agents like halothane. Beta-blockers and calcium channel blockers can exacerbate the cardiovascular depression produced by sevoflurane. The interaction between sevoflurane and certain carbon dioxide absorbents producing compound A is primarily a concern with low fresh gas flows in circle systems, which are rarely used in small mammal anesthesia where non-rebreathing circuits predominate.

Interactions between sevoflurane anesthesia and dietary factors or supplements are generally minimal. Pre-anesthetic fasting protocols vary by species and should be followed appropriately, recognizing that small mammals have different requirements than dogs or cats. Ferrets can be fasted for short periods to reduce aspiration risk, while rodents and rabbits generally should not be fasted due to their continuous eating patterns and gastrointestinal physiology. Most vitamins and supplements do not interact meaningfully with sevoflurane. Patients receiving herbal supplements should have these documented, as some herbal products can affect cardiovascular function or coagulation, which are relevant concerns during anesthesia even without direct sevoflurane interaction.

Safe and commonly used drug combinations with sevoflurane form the foundation of balanced anesthesia protocols providing superior outcomes compared to any single agent. Premedication protocols typically include sedatives like midazolam that reduce stress and induction requirements. Opioid analgesics provide pain control and allow reduced sevoflurane concentrations, with common choices including buprenorphine, butorphanol, and hydromorphone. Anticholinergic agents may be included to prevent bradycardia, particularly in rabbits. Local anesthetic techniques can dramatically reduce sevoflurane requirements for procedures affecting specific body regions. Intravenous or intraosseous fluid support maintains cardiovascular stability. Post-operative analgesics are essential as sevoflurane provides no residual pain control after discontinuation.

General precautions for sevoflurane anesthesia in small mammals encompass the fundamental risks inherent to general anesthesia in these challenging patients regardless of specific agent choice. Small mammals present higher anesthetic risk than dogs or cats due to their limited physiologic reserves, rapid heat loss, high metabolic rates requiring precise monitoring, and small body sizes that make intervention difficult. No anesthetic episode should be undertaken without clear medical justification, and the procedure's benefits must outweigh anesthetic risks. Thorough pre-anesthetic evaluation including physical examination and species-appropriate diagnostics helps identify patients at elevated risk who require modified protocols or special precautions.

Species-specific warnings for sevoflurane reflect the unique physiology and common conditions affecting different small mammals. Rabbits maintain their sensitivity to respiratory depression regardless of inhalant agent, with relatively high anesthetic mortality rates that demand vigilant monitoring and respiratory support readiness. Guinea pigs and chinchillas have challenging airway anatomy and stress sensitivity, benefiting from sevoflurane's smooth induction but still requiring careful management. Small rodents have metabolic rates so rapid that problems can develop within seconds, though sevoflurane's fast kinetics allow equally rapid intervention. Ferrets may have underlying adrenal disease, insulinoma, or cardiac conditions that affect anesthetic risk. Hedgehogs frequently have subclinical disease that may manifest under anesthetic stress.

Monitoring requirements during sevoflurane anesthesia should be comprehensive despite technical challenges posed by small patient size. Continuous heart rate monitoring via esophageal stethoscope, Doppler flow detector, or electrocardiogram provides essential cardiovascular assessment. Respiratory rate and effort require continuous visual observation with preparation for ventilatory support. Pulse oximetry provides oxygen saturation data when appropriately sized probes are available. Temperature monitoring is critical given rapid heat loss in small anesthetized mammals. Anesthetic depth assessment through reflex testing and physiologic parameter observation guides vaporizer adjustments. Blood pressure monitoring, though technically challenging in very small patients, provides valuable cardiovascular information in larger small mammals.

Human safety considerations for sevoflurane center on occupational exposure to waste anesthetic gases. Effective scavenging systems must capture exhaled gases to prevent workplace accumulation. Pregnant personnel should be particularly cautious about chronic anesthetic gas exposure. Adequate room ventilation supplements active scavenging, especially during chamber inductions where some gas leakage is unavoidable. Sevoflurane is not flammable at clinical concentrations but should be stored away from heat and ignition sources. The liquid can cause skin and eye irritation on direct contact, requiring careful handling during vaporizer filling. Environmental considerations include proper disposal of unused agent and contaminated materials according to local regulations.

Storage and management considerations during patient treatment focus on maintaining appropriate patient conditions throughout anesthesia. Active warming via circulating water blankets, forced air warmers, or other appropriate devices is essential to prevent hypothermia. Patients should be positioned to optimize respiratory function, particularly important during procedures on certain body regions. Continuous monitoring must be maintained from induction through full recovery. Recovery should occur in a quiet, warm, safe environment. Despite sevoflurane's rapid awakening characteristics, full coordination may take longer to return, requiring continued observation and protection from injury. Reuniting recovered patients with cagemates should wait until normal behavior returns.

Storage requirements for sevoflurane involve protecting the volatile liquid from conditions that could affect its stability, potency, or safety. The medication should be stored at controlled room temperature, typically between fifteen and thirty degrees Celsius, in a cool location away from excessive heat that could increase vapor pressure within the container. Sevoflurane bottles should be kept tightly closed when not in use to prevent evaporation and environmental contamination with anesthetic vapors. Light protection is less critical for sevoflurane than some other pharmaceuticals, but storage away from direct sunlight remains good practice. The storage area should be well-ventilated to disperse any vapors from minor container handling. Sevoflurane should be stored in its original container with labeling intact and kept away from oxidizing materials and ignition sources.

Shelf life and stability of sevoflurane in unopened original containers is generally excellent, with manufacturer-assigned expiration dates typically extending several years from production. Once opened, sevoflurane remains stable for extended periods when properly recapped and stored after each use. Vaporizers specifically calibrated for sevoflurane should be used, and cross-contamination with other inhalant anesthetics avoided to prevent unpredictable delivered concentrations. Vaporizer maintenance including inspection of seals and calibration verification should follow manufacturer recommendations. Sevoflurane that has changed color significantly, developed precipitates, or has an unusual odor should not be used. The interaction between sevoflurane and certain carbon dioxide absorbents producing degradation products is primarily a concern in circle breathing systems with low fresh gas flows rarely used in small mammal anesthesia.

Safe handling and disposal of sevoflurane requires attention to personal and environmental protection throughout the medication's lifecycle. Vaporizer filling should be performed in well-ventilated areas using proper technique to minimize spillage and vapor release. Familiarity with the specific filling mechanism of the sevoflurane vaporizer in use prevents accidents. Personal protective equipment including gloves provides sensible protection when handling the liquid directly. Disposal of unused sevoflurane or cleaning solutions containing the agent should follow local pharmaceutical waste regulations. Empty containers may require special handling as hazardous waste depending on jurisdiction. Spills should be addressed through ventilation and evaporation in safe areas or cleanup with appropriate absorbent materials followed by proper disposal. Workplace monitoring for anesthetic gas exposure may be advisable in facilities using large quantities of volatile anesthetics.

Hamsters, gerbils, mice, and rats benefit substantially from sevoflurane's rapid induction and recovery characteristics given their tiny body sizes, extremely high metabolic rates, and limited physiologic reserves. These small rodents can transition through dangerous intermediate anesthetic planes quickly with sevoflurane, reducing the vulnerable period during induction. The pleasant odor minimizes breath-holding and struggling during chamber or mask induction. Rapid recovery allows faster return to eating, which is important for animals with high caloric requirements and limited reserves. Precise temperature management remains essential as these patients lose heat rapidly regardless of anesthetic agent. Gerbils, which may be seizure-prone, do not appear to have elevated seizure risk with sevoflurane. Hamsters benefit from reduced handling stress with faster anesthetic transitions.

Guinea pigs and chinchillas represent species where sevoflurane's smooth induction characteristics provide particular value given their stress sensitivity and respiratory vulnerability. Both species have challenging airway anatomy making intubation difficult, so mask maintenance is typical, and the non-pungent sevoflurane vapor reduces struggling during mask application. Guinea pigs prone to respiratory disease may benefit from reduced breath-holding during induction compared to more irritating agents. Chinchillas' sensitivity to heat makes rapid recovery valuable for reducing time spent under warming devices. Both species must be monitored carefully for appetite return following anesthesia, as gastrointestinal stasis risk remains regardless of anesthetic agent. Offering favorite foods immediately upon adequate recovery encourages normal gut function restoration.

Ferrets generally handle sevoflurane anesthesia excellently, with their larger size among small mammals allowing more reliable monitoring and easier airway management including intubation. The rapid induction and recovery characteristics of sevoflurane benefit ferrets with insulinoma, where minimizing anesthetic time reduces hypoglycemia risk. Ferrets with adrenal disease or cardiac conditions may benefit from sevoflurane's cardiovascular profile. Pre-anesthetic blood glucose testing is advisable given insulinoma prevalence in ferrets. The smooth recovery from sevoflurane reduces emergence excitement that some ferrets display. These active, curious animals require secure recovery housing to prevent escape or injury during the brief residual impairment period following rapid awakening.

Hedgehogs, sugar gliders, and other exotic small mammals each present unique considerations that may influence sevoflurane selection. Hedgehogs' defensive curling during induction attempts may be overcome more quickly with sevoflurane's rapid onset, reducing handling time and stress. Their common subclinical respiratory or cardiac disease makes predictable anesthetic response valuable. Sugar gliders are extremely stress-sensitive and very small, benefiting from both the smooth induction and rapid recovery of sevoflurane. Their tendency toward self-mutilation when stressed makes fast recovery important for early behavioral assessment. Other exotic small mammals including degus, prairie dogs, and various pocket pets may be encountered, and sevoflurane's characteristics generally favor its use when available, though consultation with exotic animal specialists is advisable for unfamiliar species to identify any specific concerns.

Same-class alternatives to sevoflurane include isoflurane, which remains the most commonly used inhalant anesthetic in small mammal practice due to its lower cost despite sevoflurane's superior kinetic properties. Isoflurane provides reliable anesthesia with well-established safety data but has slower induction and recovery and a more pungent odor that may cause breath-holding. Desflurane offers even faster kinetics than sevoflurane but requires a heated vaporizer due to its low boiling point and may cause more airway irritation. Halothane is rarely used in modern practice due to cardiac sensitization risks and hepatotoxicity potential. Nitrous oxide can supplement primary inhalant agents to reduce their required concentrations but requires careful management to prevent hypoxia during recovery and has limited application in small mammals.

Different-class alternatives for achieving anesthesia in small mammals include injectable protocols that may be selected when inhalant equipment is unavailable, when specific patient factors favor injectable techniques, or based on practitioner preference. Ketamine combined with alpha-2 agonists like dexmedetomidine or medetomidine provides reliable immobilization with the advantage of alpha-2 reversibility, though the ketamine component is not reversible. Alfaxalone is a newer injectable agent with a favorable safety profile suitable for use alone or in combinations. Propofol provides rapid induction suitable for intubation followed by inhalant maintenance in patients with venous access. The choice between inhalant and injectable techniques depends on procedure requirements, patient factors, equipment availability, and practitioner expertise.

Combination therapy options using sevoflurane as the maintenance agent represent standard modern practice for optimizing small mammal anesthesia outcomes. Premedication with sedatives such as midazolam reduces patient stress, smooths induction further, and decreases sevoflurane requirements. Opioid analgesics including buprenorphine, butorphanol, or hydromorphone provide pre-emptive and intraoperative analgesia while allowing reduced inhalant concentrations. Alpha-2 agonists offer profound sedation and analgesia with significant inhalant-sparing effects but require monitoring for cardiovascular effects. Local and regional anesthesia techniques, where anatomically feasible, dramatically reduce sevoflurane requirements for procedures in specific body regions. Continued post-operative analgesic administration is essential as sevoflurane provides no residual pain control. These multimodal balanced anesthesia approaches improve patient safety and outcomes compared to single-agent techniques.